Efficacy and Safety of sofosbuvir/velpatasvir for HCV infected patients with decompensated LC

Efficacy and Safety of sofosbuvir/velpatasvir for HCV infected patients with decompensated LC - Efficacy and Safety of sofosbuvir/velpatasvir

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050343

Enrollment

Registered

2023-02-14

Start date

2018-12-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HCV infected patients with decompensated LC

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with HCV related decompensated LC 2) Patients aged 20 years or older at the time of consent 3) Patients who received an adequate explanation prior to the study and provided written consent for participation in the study

Exclusion criteria

Exclusion criteria: 1 patients judged to be inappropriate to participate in the study by the attending physician 2 patients judged to be inappropriate to participate in the study by the primary physician

Design outcomes

Primary

Measure	Time frame
The rate of sustained virological response at 12 weeks after SOF/VEL completion	—

Countries

Japan

Contacts

Public ContactGOKI SUDA

Hokkaido University Hospital Department of Gastroenterology and Hepatology

gsudgast@pop.med.hokudai.ac.jp0117161161

Outcome results